NEW YORK (GenomeWeb News) – Spanish firms Biotools and 2B BlackBio today announced a licensing deal that allows Silanes Laboratories to develop and commercialize diagnostic kits based on their technologies.
The global licensing agreement covers products and the transfer of technology to Silanes, a Mexican pharmaceutical firm, and allows Silanes to develop kits based on nucleic acid amplification technologies and stabilization of complex reaction mixtures patented by Biotools, as well as BlackBio's "accelerated high-sensitivity microsequencing patent."
Silanes will be allowed to develop new products and systems based on the licensed technologies.
BlackBio provides solutions through high-sensitive microsequencing and focuses on the areas of metabolism, oncology, cardiovascular and microbiology. Biotools provides reagents, applications, and technologies for research in molecular biology.
Terms of the deal were not disclosed.